Human TGF-Beta1 ELISA Kit

Objective: To determine the influence of high-risk HPV genotype on outcomes in HNSCC patients. Materials and Methods: This is a retrospective analysis of The Cancer Genome Atlas HNSCC cohort. Results: Using multivariate Cox regression analysis, we revealed that HPV33 + HNSCC patients have inferior overall survival compared to HPV16 + HNSCC patients independent of anatomical site (HR 3.59, 95% CI 1.58-8.12; p = 0.002). A host anti-viral immune response, apolipoprotein B mRNA editing enzyme, and catalytic polypeptide-like mutational signature, was under represented and, aneuploidy and 3p loss were more frequent in HPV33 + tumors. A deconvolution RNA-Seq algorithm to infer immune cell fractions revealed that CD8 + cytotoxic T-cell infiltration was reduced in HPV33+ compared to HPV16 + tumors (1.3% vs. 2.7%, p = 0.007). TGFB1, a negative modulator of T-cell infiltration and function, showed expression and pathway enrichment in HPV33 + tumors. Conclusions: Our work reveals that HPV genotype, in particular HPV33, has a powerful impact on HNSCC patient survival. We argue that p16 immunohistochemistry as a surrogate biomarker for HPV + status will lead to sub-optimal risk stratification and advocate HPV genotype testing as standard of care.

TGFb is involved in various biological processes, including development, differentiation, growth regulation, and epithelial-mesenchymal transition (EMT). In TGFb/Smad signaling, receptor-activated Smad complexes activate or repress their target gene promoters. Smad cofactors are a group of Smad-binding proteins that promote recruitment of Smad complexes to these promoters. Long noncoding RNAs (lncRNA), which behave as Smad cofactors, have thus far not been identified. Here, we characterize a novel lncRNA EMTassociated lncRNA induced by TGFb1 (ELIT-1). ELIT-1 was induced by TGFb stimulation via the TGFb/Smad pathway in TGFb-responsive cell lines. ELIT-1 depletion abrogated TGFb-mediated EMT progression and expression of TGFb target genes including Snail, a transcription factor critical forEMT. A positive correlation between high expression of ELIT-1 and poor prognosis in patients with lung adenocarcinoma and gastric cancer suggests that ELIT-1 may be useful as a prognostic and therapeutic target. RIP assays revealed that ELIT-1 bound to Smad3, but not Smad2. In conjunction with Smad3, ELIT-1 enhanced Smad-responsive promoter activities by recruiting Smad3 to the promoters of its target genes including Snail, other TGFb target genes, and ELIT-1 itself. Collectively, these data show that ELIT-1 is a novel trans-acting lncRNA that forms a positive feedback loop to enhance TGFb/Smad3 signaling and promote EMT progression. Significance: This study identifies a novel lncRNA ELIT-1 and characterizes its role as a positive regulator of TGFb/Smad3 signaling and EMT.